| __timestamp | HUTCHMED (China) Limited | Ligand Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 72049000 | 9136000 |
| Thursday, January 1, 2015 | 110777000 | 5807000 |
| Friday, January 1, 2016 | 156328000 | 5571000 |
| Sunday, January 1, 2017 | 175820000 | 5366000 |
| Monday, January 1, 2018 | 143944000 | 6337000 |
| Tuesday, January 1, 2019 | 160152000 | 11347000 |
| Wednesday, January 1, 2020 | 188519000 | 30419000 |
| Friday, January 1, 2021 | 258234000 | 62176000 |
| Saturday, January 1, 2022 | 311103000 | 52827000 |
| Sunday, January 1, 2023 | 384447000 | 35049000 |
Data in motion
In the ever-evolving landscape of the pharmaceutical industry, understanding cost dynamics is crucial. From 2014 to 2023, HUTCHMED (China) Limited and Ligand Pharmaceuticals Incorporated have shown distinct trends in their cost of revenue. HUTCHMED's cost of revenue surged by over 430%, starting from approximately $72 million in 2014 to nearly $384 million in 2023. This growth reflects the company's expanding operations and market reach. In contrast, Ligand Pharmaceuticals exhibited a more modest increase of around 280%, with costs rising from about $9 million to $35 million over the same period. This disparity highlights differing business models and market strategies. While HUTCHMED's aggressive expansion is evident, Ligand's steady growth suggests a more conservative approach. These trends offer valuable insights into the strategic priorities and operational efficiencies of these two industry players.
Cost of Revenue: Key Insights for Eli Lilly and Company and Ligand Pharmaceuticals Incorporated
Bristol-Myers Squibb Company vs HUTCHMED (China) Limited: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Gilead Sciences, Inc. vs Ligand Pharmaceuticals Incorporated
Comparing Cost of Revenue Efficiency: Vertex Pharmaceuticals Incorporated vs Ligand Pharmaceuticals Incorporated
Cost of Revenue: Key Insights for Zoetis Inc. and HUTCHMED (China) Limited
Comparing Cost of Revenue Efficiency: Regeneron Pharmaceuticals, Inc. vs Ligand Pharmaceuticals Incorporated
Cost of Revenue: Key Insights for Biogen Inc. and Ligand Pharmaceuticals Incorporated
Comparing Cost of Revenue Efficiency: Neurocrine Biosciences, Inc. vs Ligand Pharmaceuticals Incorporated
Cost of Revenue: Key Insights for Halozyme Therapeutics, Inc. and HUTCHMED (China) Limited
Cost of Revenue Trends: Vericel Corporation vs Ligand Pharmaceuticals Incorporated
Cost Insights: Breaking Down Ligand Pharmaceuticals Incorporated and MiMedx Group, Inc.'s Expenses